Industry News

BiondVax Pharmaceuticals Ltd. announced today that the last participant in a European Phase 2 b clinical trial of M-001, its universal flu vaccine candidate, has completed their final visit. Conducted in collaboration with the EU-sponsored UNISEC consortium, the trial is designed to evaluate the safety and immunogenicity of M-001 when used ahead of a pandemic influenza vaccine."/>
BiondVax Phase 2b European Trial: Last Patient Out
Ensign Group declared on Tuesday that it will pay a quarterly dividend of USD0.04 per share of its common stock. Shareholders of record as of 30 September 2016 will receive the cash dividend on or before 31 October 2016.. According to the home health care company, it has been paying dividends since 2002.."/>
The Ensign Group reports USD0.04 per share dividend
Integra LifeSciences Holdings reported on Tuesday that the first three procedures using the Integra Cadence total ankle system have been completed in Europe. The ankle surgeries were carried out by Dr Thibaut Leemrijse of the Foot and Ankle Institute, Parc Lopold Clinic, Brussels, Belgium. Following the European launch of the Cadence system, the company's new improved designs as well as advanced surgical education programmes are fueling the growth of the..."/>
Integra LifeSciences reports first three surgical procedures with Cadence total ankle system in Europe
Neuralstem, Inc., a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced that it has reached over 50% enrollment in its Phase 2 clinical trial evaluating NSI-189, a novel neurogenic small molecule, for the treatment of major depressive disorder.. The ongoing Phase 2 MDD study is testing two doses of NSI-189, a small molecule in an oral tablet formulation."/>
Neuralstem Achieves 50% Enrollment in NSI-189 Phase 2 Trial in Major Depressive Disorder
Stellar Biotechnologies, Inc., the leader in sustainable manufacture of Keyhole Limpet Hemocyanin, will present at the VIII Simposio Internacional de Sanidad e Inocuidad Acuícola in Ensenada, Baja California, Mexico, September 22-23, 2016.. The VIII Symposium on Aquaculture Health and Safety is a notable event bringing together a cross-disciplinary group of international representatives to review developments, trends and policy related to..."/>
Stellar Biotechnologies to Present at International Aquaculture Symposium
Cellectar Biosciences, Inc., an oncology-focused biotechnology company, today announces that Jim Caruso, president and CEO of Cellectar, will present at the OktoberINVESTfest presented by Joseph Gunnar& Co. on September 28, 2016.. The company’ s presentation at OktoberINVESTfest will be held at 11:05 AM ET at The New York Academy of Sciences at 250 Greenwich Street, 40 th Floor, Room 4, in New York City. Caruso’ s presentation will be webcast via..."/>
Cellectar Biosciences To Present at OktoberINVESTfest
Skyline Medical Inc., producer of the FDA-approved STREAMWAY ® System for automated, direct-to-drain medical fluid disposal, announces the signing of a partnership and exclusive reseller agreement with GLG Pharma, LLC.. Under the terms of the agreement, GLG intends to develop rapid diagnostic tests that utilize fluid and tissue collected by the STREAMWAY System during procedures. Skyline Medical will issue common stock to GLG in four separate..."/>
Skyline Medical and GLG Pharma Enter into Partnership to Develop Diagnostic Tests for Skyline’s STREAMWAY System
Aratana Therapeutics, Inc., a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics will participate in a panel discussion at the Jefferies Animal Health Leadership Summit today in London titled "Competing with Giants: Strategies to Succeed in a..."/>
Aratana Therapeutics to Participate in Jefferies Animal Health Leadership Summit
ViewRay, Inc. announced today that the National Cancer Center in Tokyo, Japan has purchased a MRIdian System, the world's first and only clinical MRI-guided radiation therapy system. The MRIdian System is a unique medical instrument that integrates full-time MR imaging, cobalt radiation delivery, and intelligent software automation. Using the MRIdian System, clinicians can see soft tissue, and visualize and adjust the dose— all in real-time,..."/>
National Cancer Center Japan Purchases ViewRay MRIdian System
Keryx Biopharmaceuticals, Inc,, a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced it will webcast its corporate presentation at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27 at 4:00 p.m. Eastern Time.. A live audio webcast of the presentation will be accessible from Keryx’ s website at http://investors.keryx.com within the Investor Relations section under“..."/>
Keryx Biopharmaceuticals to Webcast its Presentation at Ladenburg Thalmann’s 2016 Healthcare Conference
EyeGate Pharmaceuticals, Inc.,, a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that Stephen From, President& Chief Executive Officer of EyeGate, is scheduled to present at the 2016 Aegis Capital Corp. Investment Growth Conference, being held September 21 and 22, 2016 at the Encore at Wynn Las Vegas in Las Vegas, NV.. Details of the presentations..."/>
EyeGate Pharmaceuticals to Present at the 2016 Aegis Capital Conference
Hemostemix Inc., a clinical-stage autologous cell-therapy company, announces today that it has successfully completed the annual re-certification of its Israeli manufacturing site and lab facility. The re-certification complies with the cGMP standards for manufacturing of biological products for use in humans and fulfills the requirements of the US-FDA and other international health authorities. The re-certification was conducted by QCC..."/>
Hemostemix Announces Successful Re-Certification of its Israeli Manufacturing Facility
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company has selected the first development candidate from its proprietary immunotherapy discovery platform, Cloudbreak™. Cloudbreak is the first platform of its kind designed specifically to create..."/>
Cidara Therapeutics Selects First Development Candidate from its CloudbreakTM Immunotherapy Discovery Platform
bluebird bio, Inc., a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that the European Medicines Agency has granted access to its Priority Medicines scheme for LentiGlobin drug product in the treatment of patients with transfusion-dependent beta-thalassemia. The PRIME initiative provides enhanced support and..."/>
LentiGlobin™ Investigational Gene Therapy for Transfusion-Dependent Beta-Thalassemia Accepted into European Medicines Agency’s PRIME Program
MYnd Analytics, Inc.. We appreciate your continued support. We have produced disruptive results for one of the most challenging problems in medicine: reducing trial and error treatment in mental health."/>
MYnd Analytics Letter to Shareholders
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced that top-line data from the Phase III SUNRISE trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell lung cancer will be presented as..."/>
Peregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 Congress
Aurinia Pharmaceuticals Inc., today announced that it will host a Lupus Nephritis expert breakfast on Friday, September 30 th from 8:00am to 9:30am EDT in New York. The Company will review the recently released top-line results from the AURA-LV Phase 2 b study in patients with active LN and announce additional data, including pre-specified analyses, secondary..."/>
Aurinia Pharmaceuticals to Host Lupus Nephritis (LN) Breakfast and Webcast on September 30th in New York
OncBioMune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces the release of a patient testimonial video by prostate cancer survivor Stephen Karalekas. The video tells the story of Mr. Karalekas and his experience with the OncBioMune team and the Company's experimental immunotherapy prostate cancer vaccine, ProscaVax."/>
Prostate Cancer Free for 10 Years, Stephen Karalekas Thanks OncBioMune for ProscaVax in Testimonial Video
Universal American company, announced today that its president, Jeffery Spight, will present at the National Association of Accountable Care Organizations Fall 2016 Conference, September 28-30 at the Capital Hilton in Washington, D.C. CHS currently partners with approximately 5,000 providers, mostly primary care physicians, in one Next Generation ACO Model and 22 Medicare Shared Savings Program ACOs, covering 239,000..."/>
Collaborative Health Systems to Present at 2016 National Association of Accountable Care Organizations (NAACOS) Conference
Vericel Corporation, a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, and Gerard Michel, chief financial officer and vice president of corporate development, will present at the Ladenburg Thalmann 2016 Healthcare Conference at Sofitel Hotel in New York City, NY on Tuesday, September 27, 2016, at 11:30am Eastern time.."/>
Vericel to Present at Ladenburg Thalmann Healthcare Conference
athenahealth, Inc., a leading provider of cloud-based services and mobile applications for medical groups and health systems, today launched athenaInsight, a daily news hub..."/>
Athenahealth Launches athenaInsight, a New Editorial Hub Reporting from the Heart of the Healthcare Internet
Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the appointment of Nancy L. Boman, M.D., Ph.D. as senior vice president of regulatory affairs and pharmacovigilance. Boman will be responsible for developing and implementing the regulatory strategy and pharmacovigilance program of ALD403 for migraine prevention as it advances through pivotal trials and..."/>
Alder BioPharmaceuticals Appoints Nancy L. Boman, M.D., Ph.D., Senior Vice President of Regulatory Affairs and Pharmacovigilance

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology754 Articles
Consumer Discretionary655 Articles
Financials504 Articles
Industrials427 Articles
Health Care424 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.